CONMED Corp. 10-Q Summary: Quarter Ended September 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the three and nine months ended September 30, 2001, for CONMED Corporation, a medical technology company specializing in arthroscopic sports medicine instruments, powered surgical instruments, and advanced medical devices. The company operates as a single segment. The reporting period includes the impact of a 3-for-2 common stock dividend declared in August 2001 and the acquisition of the remaining assets of Imagyn Medical Technologies' minimally invasive surgical business in June 2001.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 2001 | 9 Months Ended Sep 2001 |
|---|---|---|
| Net Sales | $105,318 | $315,398 |
| Cost of Sales | $51,332 | $150,971 |
| Gross Margin (Reported) | 51.2% | 52.2% |
| Gross Margin (Adjusted*) | 52.1% | 52.4% |
| Operating Income | $15,466 | $49,984 |
| Net Income | $5,015 | $16,752 |
| Diluted EPS | $0.20 | $0.70 |
| Operating Cash Flow (9mo) | $23,572 | |
| Total Debt (Current + Long-term) | $388,407 | |
| Cash and Equivalents | $2,015 | |
| Working Capital | $121,533 |
*Adjusted to exclude $886,000 in nonrecurring acquisition-related costs included in Cost of Sales.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.5% in the quarter and 7.5% for the nine-month period compared to 2000. Endoscopy sales surged 464% in the quarter and 212% for the nine months, largely driven by the Imagyn acquisition.
- Profitability: Net income rose 83.8% in the quarter and 22.7% for the nine months. Operating income increased 18.1% (quarter) and 6.8% (nine months).
- Interest Expense: Interest expense decreased significantly (13.6% in the quarter, 6.5% for nine months) due to lower weighted average interest rates on term loans and the revolving credit facility (approx. 5.6% in 2001 vs. 8.5%+ in 2000).
- Acquisition Costs: The company incurred $886,000 in nonrecurring charges in Q3 2001 related to transitioning Imagyn manufacturing operations. An additional $500,000 in similar costs is expected in Q4 2001.
- Balance Sheet: Total assets increased to $739.3 million from $679.6 million, driven by property, plant, and equipment additions and goodwill from acquisitions. Cash decreased to $2.0 million from $3.5 million at year-end 2000.
Outlook, Risks, and Unusual Items
- Acquisition Integration: The company is integrating Imagyn product lines, expecting continued nonrecurring costs in Q4 2001. The acquisition provides a significant presence in the laparoscopic instrument market with expected annual revenues of $18.0 to $20.0 million.
- Liquidity and Debt: The company maintains a $100 million revolving credit facility with $39 million available as of September 2001. Term loans aggregate $173.9 million. A new $50 million accounts receivable securitization facility was established in November 2001, with initial proceeds of $40 million used to repay bank loans.
- Accounting Changes: The company is assessing the impact of new FASB standards (SFAS 141 and 142) regarding business combinations and goodwill, which will discontinue goodwill amortization upon adoption.
- Risks: Management highlights risks including general economic conditions, competition, regulatory enforcement, patent litigation, and foreign operations risks (currency devaluation, expropriation).
Investor Verification Checklist
- Acquisition Synergies: Verify the timeline and cost of integrating Imagyn manufacturing to confirm the $500,000 Q4 cost estimate and future margin impact.
- Debt Covenants: Review the specific financial ratios required by the credit facility and Notes to ensure compliance, particularly given the high debt load relative to cash.
- Receivables Securitization: Confirm the terms of the new $50 million securitization facility and its impact on future liquidity and balance sheet presentation.
- Product Mix: Monitor the shift in product mix, as the decline in higher-margin orthopaedic sales as a percentage of total sales contributed to a slight decrease in gross margin percentage.
- Interest Rate Exposure: Assess the effectiveness of the $50 million interest rate swap in hedging against rising rates on the remaining floating-rate debt.